Spots Global Cancer Trial Database for apalutamide
Every month we try and update this database with for apalutamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | NCT05202301 | Prostate Cancer | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | NCT05422911 | Metastatic Canc... Neoplasm, Prost... | Abiraterone ace... Apalutamide Enzalutamide | - | James J. Peters Veterans Affairs Medical Center | |
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | NCT04523207 | Prostatic Neopl... | Apalutamide ADT Relugolix | 18 Years - | Janssen Research & Development, LLC | |
| Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | NCT05534646 | Castration-resi... | Apalutamide Carotuximab | 18 Years - | Cedars-Sinai Medical Center | |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | NCT03569280 | Castration-Resi... | Enzalutamide or... | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases | NCT05740488 | Prostate Cancer... | Apalutamide 89Sr Luteinizing Hor... | 18 Years - | Zhujiang Hospital | |
| Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | NCT03360721 | Castration-Resi... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | NCT03821792 | Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | NCT05818683 | Metastatic Cast... | JNJ-78278343 Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | NCT05901649 | Metastatic Horm... | Apalutamide Enzalutamide | 18 Years - | Janssen-Cilag Ltd. | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | NCT04926181 | Small Cell Neur... Prostate Cancer Small Cell Carc... | Apalutamide Cetrelimab | 18 Years - | University of California, San Francisco | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | NCT04557059 | Prostatic Neopl... | Radiotherapy LHRHa Apalutamide | 18 Years - | Janssen Pharmaceutica N.V., Belgium | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | NCT05960578 | Castration-Resi... Prostate Adenoc... | Apalutamide Biopsy Biospecimen Col... Computed Tomogr... Golimumab Magnetic Resona... PSMA PET Scan | 18 Years - | University of Washington | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | NCT04557059 | Prostatic Neopl... | Radiotherapy LHRHa Apalutamide | 18 Years - | Janssen Pharmaceutica N.V., Belgium | |
| Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | NCT02867020 | Prostate Cancer | Apalutamide Abiraterone ADT Prednisone | 18 Years - | Latin American Cooperative Oncology Group | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| Evaluation of Fapi-pet in Prostate Cancer. | NCT05192694 | Prostate Cancer | Computed tomogr... | 18 Years - 100 Years | Helsinki University Central Hospital | |
| A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | NCT05901649 | Metastatic Horm... | Apalutamide Enzalutamide | 18 Years - | Janssen-Cilag Ltd. | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) | NCT05778097 | Prostate Cancer Biochemical Rec... High Risk | Apalutamide 60m... Androgen depriv... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer | NCT03523338 | Prostatic Neopl... | Apalutamide ADT (Standard o... | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer | NCT03523442 | Prostatic Neopl... | Apalutamide | 18 Years - | Janssen Research & Development, LLC | |
| An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings | NCT05362149 | Non-metastatic ... | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | NCT06274047 | Androgen Axis S... Prostatectomy Prostate Cancer | Apalutamide Androgen Depriv... | 18 Years - | M.D. Anderson Cancer Center | |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | NCT05212857 | Prostate Cancer | Leuprolide acet... Goserelin aceta... Triptorelin ace... Degarelix aceta... Abiraterone ace... Apalutamide Enzalutamide Local treatment... Radiotherapy fo... Radiotherapy fo... | 18 Years - 80 Years | Fudan University | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | NCT02789878 | Prostate Cancer | Goserelin Prednisone Abiraterone Apalutamide | 18 Years - 80 Years | Instituto do Cancer do Estado de São Paulo | |
| Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP | NCT03899077 | Cancer of Prost... | Apalutamide Leuprorelin Ace... Goserelin Aceta... Triptorelin Pam... Degarelix aceta... | 18 Years - | Cancer Research Antwerp | |
| A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer | NCT02906605 | Prostatic Neopl... | JNJ-809 Apalutamide | 18 Years - | Janssen Research & Development, LLC | |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | NCT06067269 | Prostate Adenoc... Stage II Prosta... Stage IIIA Pros... Stage IIIB Pros... | Apalutamide Biospecimen Col... Computed Tomogr... Gallium Ga 68 G... Guided Stereota... Multiparametric... Positron Emissi... Questionnaire A... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | NCT04530552 | Localized Prost... Prostate Adenoc... Stage I Prostat... Stage II Prosta... | Apalutamide Biospecimen Col... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | NCT02578797 | Castration-Resi... | Apalutamide | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05295927 | Prostatic Neopl... | EPI-7386 Abiraterone Ace... Prednisone or P... Apalutamide | 18 Years - | Janssen Research & Development, LLC | |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | NCT04947254 | Prostate Carcin... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IVA Prost... | Abiraterone Ace... Antiandrogen Th... Apalutamide Biopsy Niraparib Prednisone Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | NCT03569280 | Castration-Resi... | Enzalutamide or... | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | NCT05367440 | Metastatic Pros... | AZD5305 Enzalutamide Abiraterone Ace... Darolutamide Apalutamide | 18 Years - 130 Years | AstraZeneca | |
| Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | NCT03777982 | Prostate Cancer | Prednisone Apalutamide Abiraterone Ace... LHRH Agonist or... | 18 Years - | Dana-Farber Cancer Institute | |
| Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | NCT03298087 | Newly Diagnosed... | radical prostat... stereotactic bo... Leuprolide apalutamide abiraterone | 18 Years - | VA Office of Research and Development | |
| Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | NCT03279250 | Prostate Adenoc... Stage IIB Prost... Stage IIC Prost... Stage IIIA Pros... Stage IIIC Pros... | Abiraterone Ace... Apalutamide Gonadotropin-re... Prednisone Radical Prostat... | 18 Years - | M.D. Anderson Cancer Center | |
| Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | NCT02721979 | Prostate Adenoc... | Apalutamide Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | University of Washington | |
| Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy | NCT04295447 | Prostatic Neopl... | Standard of car... Apalutamide 60M... | 18 Years - | Universität Münster | |
| Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | NCT04409288 | Prostate Cancer | Apalutamide Enzalutamide | 18 Years - | Chinese University of Hong Kong | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings | NCT06013475 | Non-metastatic ... | Apalutamide Darolutamide (B... Enzalutamide | 18 Years - | Bayer | |
| TherApeutics in Early ProState Cancer (TAPS02) | NCT05191680 | Prostate Cancer | Apalutamide Ora... Placebo | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | NCT02721979 | Prostate Adenoc... | Apalutamide Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | University of Washington | |
| Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma | NCT04567875 | Castration-resi... | No Intervention... | - | Ospedale Andrea Tortora di Pagani | |
| An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States | NCT06204302 | Non-metastatic ... Non-metastatic ... | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| Therapeutics in Active Prostate Cancer Surveillance | NCT03365297 | Prostate Cancer | Apalutamide | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC | NCT02913196 | Prostate Cancer... | Apalutamide Abiraterone ace... Docetaxel Prednisone | 18 Years - | Weill Medical College of Cornell University | |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | NCT03141671 | Prostate Cancer | GnRH Bicalutamide Salvage radiati... Abiraterone Prednisone Apalutamide | 18 Years - 95 Years | Dana-Farber Cancer Institute | |
| A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | NCT03009981 | Prostate Cancer | Apalutamide LHRH Analogue Abiraterone Ace... Prednisone | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | NCT05202301 | Prostate Cancer | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | NCT04108208 | Prostatic Neopl... | Apalutamide Placebo Androgen-depriv... | 18 Years - | Janssen Research & Development, LLC | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | NCT02489318 | Prostate Cancer | Apalutamide Placebo Androgen Depriv... | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer | NCT02770391 | Prostate Cancer | Leuprolide acet... Apalutamide Radical prostat... | 18 Years - | Case Comprehensive Cancer Center | |
| A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC | NCT05884398 | Metastatic Cast... | Apalutamide Androgen-depriv... | 18 Years - | Janssen Research & Development, LLC | |
| A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | NCT05202301 | Prostate Cancer | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | NCT03903835 | Metastatic Cast... Metastatic Horm... | Enzalutamide Or... Abiraterone Ora... Carboplatin Cabazitaxel 60 ... Docetaxel Injec... Radium Chloride... Niraparib plus ... Capivasertib pl... Apalutamide Darolutamide | 18 Years - | Karolinska Institutet | |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | NCT05406999 | Neoadjuvant The... High Risk Prost... Locally Advance... Intense Endocri... | ADT Abiraterone Ace... Prednisolone ta... Enzalutamide Apalutamide Darotamide Rezvilutamide PARP inhibitor Robot-assisted ... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | NCT03821792 | Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Micro RNAs to Predict Response to Androgen Deprivation Therapy | NCT02366494 | Prostate Cancer | Bicalutamide Leuprolide Goserelin Triptorelin Docetaxel Abiraterone Apalutamide Enzalutamide | 21 Years - 85 Years | Medical College of Wisconsin | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | NCT03767244 | Prostatic Neopl... | Apalutamide Androgen Depriv... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer | NCT03523338 | Prostatic Neopl... | Apalutamide ADT (Standard o... | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | NCT04585932 | Biochemically R... Metastatic Pros... Oligometastatic... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Apalutamide Degarelix Leuprolide Acet... Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Recurrent Castr... Stage IVB Prost... Recurrent Prost... Castration-resi... | Abiraterone Apalutamide Biospecimen Col... Bone Scan Computed Tomogr... Darolutamide Degarelix Enzalutamide Goserelin Histrelin Leuprolide Magnetic Resona... Patient Observa... Positron Emissi... Prednisone Questionnaire A... Relugolix Stereotactic Bo... Triptorelin | 18 Years - | Mayo Clinic | |
| A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | NCT03093272 | Prostate Cancer | Leuprolide Acet... Prednisone Docetaxel Apalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | NCT05159245 | Advanced Cancer Solid Tumor Haematological ... | Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | NCT04423211 | Biochemically R... Metastatic Pros... Prostate Adenoc... Stage IVB Prost... | 3-Dimensional C... Apalutamide Computed Tomogr... Degarelix External Beam R... Fluciclovine F1... Goserelin Aceta... Intensity-Modul... Intensity-Modul... Leuprolide Acet... Magnetic Resona... Positron Emissi... Quality-of-Life... Questionnaire A... Relugolix Stereotactic Bo... Triptorelin Volume Modulate... | 18 Years - | Eastern Cooperative Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
